Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

Fresolimumab (fresolimumab) | Accelerate Your Fibrosis Research

Home/Drugs/Fresolimumab

Fresolimumab

fresolimumab

Phase 2a

Sponsor: Sanofi / Genzyme

Indication: FSGS / DKD

Mechanism of Action

Anti-TGF-beta monoclonal antibody

Target: TGF-β

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT00923169

Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)

Phase:PHASE1Org:National Institutes of Health Clinical Center (CC)

COMPLETEDNCT00464321

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Phase:PHASE1Org:Sanofi

COMPLETEDNCT01112293

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Phase:PHASE2Org:Abramson Cancer Center at Penn Medicine

COMPLETEDNCT00356460

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

Phase:PHASE1Org:Sanofi

COMPLETEDNCT01284322

Fresolimumab In Systemic Sclerosis

Phase:PHASE1Org:Boston University

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

No recent publications found for fresolimumab.

Validated Models

This drug has been validated in the following preclinical models: